Details for Patent: 7,713,947
✉ Email this page to a colleague
Which drugs does patent 7,713,947 protect, and when does it expire?
Patent 7,713,947 protects MAVENCLAD and is included in one NDA.
This patent has sixty-eight patent family members in thirty countries.
Summary for Patent: 7,713,947
| Title: | Cladribine regimen for treating multiple sclerosis |
| Abstract: | The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible. |
| Inventor(s): | De Luca; Giampiero (Conches/Geneva, CH), Ythier; Arnaud (Collex-Bossy, CH), Munafo; Alain (Tartegnin, CH), Lopez-Bresnahan; Maria (Lincoln, MA) |
| Assignee: | Merck Serono S.A. (Coinsins, Vaud, CH) |
| Application Number: | 11/722,018 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,713,947 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Delivery; Dosage form; |
Drugs Protected by US Patent 7,713,947
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | MAVENCLAD | cladribine | TABLET;ORAL | 022561-001 | Mar 29, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,713,947
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 04106909 | Dec 22, 2004 | |
| PCT Information | |||
| PCT Filed | December 20, 2005 | PCT Application Number: | PCT/EP2005/056954 |
| PCT Publication Date: | June 29, 2006 | PCT Publication Number: | WO2006/067141 |
International Family Members for US Patent 7,713,947
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1827461 | ⤷ Sign Up | 122018000021 | Germany | ⤷ Sign Up |
| European Patent Office | 1827461 | ⤷ Sign Up | 300930 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1827461 | ⤷ Sign Up | CR 2018 00010 | Denmark | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
